For mCRPC patients treated with 177-Lutetium-PSMA, two single-center studies reported that alterations in TP53 were not associated with 177-Lu-PSMA outcomes [78,79], whereas a larger multi-center retrospective study and a study from a phase I/II trial on 177-Lu-PSMA therapy found an association between the presence of at least one mutation in TP53, RB1 or PTEN tumor suppressors with shorter PFS and OS [80,81]. Here, FOLH1 is linked to neoplasm.